Loading...
Loading...
AVEO Oncology
AVEO and Astellas Pharma Global Development,
Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo:
4503), today announced that the U.S. Food and Drug Administration's
(FDA) Oncologic Drugs Advisory Committee (ODAC) will review the
company's New Drug Application (NDA) for tivozanib for the treatment of
patients with advanced renal cell carcinoma (RCC) during the morning
session of its meeting on May 2, 2013. ODAC reviews and evaluates data
concerning the safety and effectiveness of marketed and investigational
human drug products for use in the treatment of cancer, and makes
recommendations to the Commissioner of Food and Drugs. According to the
timelines established by the Prescription Drug User Fee Act (PDUFA), the
review of the NDA
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in